Land: Nieuw-Zeeland
Taal: Engels
Bron: Medsafe (Medicines Safety Authority)
Lenograstim 13.4 MIU
Pfizer New Zealand Limited
Lenograstim 13.4 MIU
13.4 MIU
Powder for injection
Active: Lenograstim 13.4 MIU Excipient: Arginine Hydrochloric acid Mannitol Methionine Phenylalanine Polysorbate 20
Vial, glass, 5 x single dose vials, 5 dose units
Prescription
Prescription
Chugai Pharmaceutical Co Ltd
Package - Contents - Shelf Life: Vial, glass, 5 x single dose vials - 5 dose units - 24 months from date of manufacture stored at or below 30°C 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze)
1970-01-01
pfdgrani10319 1 NEW ZEALAND DATA SHEET 1. PRODUCT NAME GRANOCYTE ® 13 lenograstim 105 µg (13.4 million IU) powder for injection GRANOCYTE ® 34 lenograstim 263 µg (33.6 million IU) powder for injection Lenograstim (rch) is expressed in a mammalian host cell system, Chinese hamster ovary (CHO) cells. Lenograstim has a molecular weight of about 20,000 Daltons and consists of 174 amino acids and approximately 4% carbohydrate. The amino acid sequence analysis of lenograstim reveals that it is identical to native G-CSF. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION GRANOCYTE ® 13: Each 5mL vial contains lenograstim (rch) 105 µg (13.4 million IU) GRANOCYTE ® 34: Each 5mL vial contains lenograstim (rch) 263 µg (33.6 million IU) For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for injection. White cake (lyophilised powder) in a glass vial with a rubber stopper and a flip off cap. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS GRANOCYTE is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation, or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapy. GRANOCYTE is also indicated to mobilise peripheral blood progenitor cells (PBPCs) with GRANOCYTE alone, or after myelosuppressive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. GRANOCYTE is also indicated to accelerate the engraftment of these cells after their reinfusion. GRANOCYTE is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis (Kostmann's syndrome). 4.2 DOSE AND METHOD OF ADMINISTRATION Dose GRANOCYTE 34 263 µg (33.6 million IU) per vial is used in patients with body surface area up to 1.8 m². GRANOCYTE 13 105 µg (13.4 million I Lees het volledige document